Compare ODC & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | SDGR |
|---|---|---|
| Founded | 1941 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 850.5M |
| IPO Year | 1994 | 2020 |
| Metric | ODC | SDGR |
|---|---|---|
| Price | $73.60 | $12.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 45.3K | ★ 1.3M |
| Earning Date | 06-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 50.45 | 45.14 |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $485,572,000.00 | $255,869,000.00 |
| Revenue This Year | N/A | $0.76 |
| Revenue Next Year | N/A | $4.60 |
| P/E Ratio | $43.57 | ★ N/A |
| Revenue Growth | 10.97 | ★ 23.29 |
| 52 Week Low | $41.37 | $10.95 |
| 52 Week High | $74.28 | $27.63 |
| Indicator | ODC | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 70.39 | 50.51 |
| Support Level | $58.40 | $11.03 |
| Resistance Level | N/A | $13.36 |
| Average True Range (ATR) | 1.79 | 0.68 |
| MACD | 0.16 | 0.05 |
| Stochastic Oscillator | 100.00 | 41.23 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.